ClinicalTrials.gov
public full text
Public Domain
A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients
The study aimed to elucidate predictive immune related biomarker to the responsiveness to the PD-L1 blockade and evaluate the dynamics of immune cells in peripheral blood from NSCLC patients during atezolizumab treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab#900625
- Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC#417561
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer#146462
- Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC#314317
- A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients#184840
Record · ID 906327
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive